On this page
- Quick answer
- Start with the question
- Why chemistry is hard to search
- Searching by subject matter
- Sources worth knowing
- A search workflow that holds up
- A worked example: an extended-release tablet of a known drug
- Common mistakes
- Checklist
- How MYCrave can help
- Search the chemistry, not just the words
- Frequently asked questions
Search for a mechanical invention and you can get a long way with good keywords and the right classification. Search for a drug and keywords fail quickly. The compound you care about may appear in a patent only as one of millions of possibilities covered by a general formula. It may be named by a code number in an early paper, by an IUPAC name nobody types the same way twice, or by a brand name in a regulatory filing. The formulation that matters may be described only in a package insert.
Indian law then adds its own layer. Section 3(d) means that a new salt, polymorph or isomer of a known drug is judged against the known substance and its known efficacy. A search that finds only patents misses half the question. This guide covers how to search pharmaceutical subject matter properly, whatever the question you are trying to answer.
Quick answer
A pharmaceutical patent search combines structure searching (exact, substructure, similarity and Markush), keyword and identifier searching (INN, CAS Registry Number, IUPAC name, code names, brand names), classification (A61K, A61P, C07D, C07K, C12N and their subgroups) and non-patent literature, including clinical papers and regulatory documents. The question decides the scope: patentability looks for anything published before your priority date, worldwide; freedom to operate looks at patents and applications in force in your markets. In India, the search should also find the known substance and its known efficacy, because section 3(d) treats salts, esters, polymorphs, isomers and other derivatives as the same substance unless they differ significantly in efficacy. For medicines, the Supreme Court read efficacy as therapeutic efficacy in Novartis AG v. Union of India (2013).
Start with the question
Pharma searches are expensive, so define the question before anyone opens a database.
- Patentability. Is our compound, form, formulation or process new and inventive over everything published before our priority date, anywhere in the world? Will section 3(d) or 3(e) be raised?
- Freedom to operate. Can we make and sell this product in India (and other markets) without infringing a patent in force? This looks at granted patents and pending applications, their claims and their legal status.
- Validity or invalidity. Is a competitor's patent open to a pre-grant representation, post-grant opposition or revocation? This looks for prior art the examiner missed.
- Landscape and expiry. What patents protect a reference product, when do they expire, and where are the gaps? Generic companies run this years before launch.
Our freedom-to-operate guide explains why an FTO answers a different question from a patentability search. The rest of this guide focuses on what is different about chemistry and medicines.
Why chemistry is hard to search
Markush formulas. A compound patent usually claims a general structure with variable groups: "wherein R1 is hydrogen, C1–C6 alkyl or halogen...". One formula can cover millions of compounds. Your molecule may fall within a formula that never names it. In Novartis, the Supreme Court discussed the difference between a compound being covered by an earlier patent's claims and being disclosed by it. Both matter: coverage for freedom to operate, disclosure for novelty and inventive step.
Names that do not match. One substance can appear as an INN, several IUPAC variants, a CAS Registry Number, a SMILES or InChI string, a company code ("ABC-1234") in early papers and a brand name later. Searching one name finds one slice of the literature.
Images, not text. Many structures are published as drawings. Text search does not see them. Chemistry databases index structures so that they can be searched as structures.
Disclosure outside patents. Journal articles, conference abstracts, theses, regulatory review documents and package inserts often disclose compounds, doses and formulations before or alongside patents.
Searching by subject matter
New chemical entities
Run an exact structure search for the compound, a substructure search for its core scaffold, a similarity search for close analogues, and a Markush search to find generic formulas that cover it. Commercial chemistry databases do this best. Free tools can take you a long way: PubChem links compounds to patent documents, SureChEMBL extracts chemistry from patent full text, and WIPO's PATENTSCOPE offers chemical structure searching. Record every identifier you used.
Salts, polymorphs, isomers and other forms
Here the search has two jobs. First, find any disclosure of the specific form, including crystal forms described by X-ray diffraction data in other patents or papers. Second, find the known substance and what is known about its efficacy. Section 3(d) asks whether the new form shows enhanced efficacy over the known substance, and the Explanation to section 3(d) deems salts, esters, ethers, polymorphs, metabolites, pure forms, particle sizes, isomers, mixtures of isomers, complexes, combinations and other derivatives to be the same substance unless they differ significantly in properties with regard to efficacy. In Novartis, the Court held that for medicines this means therapeutic efficacy, and that better physical properties such as flow, stability or bioavailability do not count by themselves unless shown to enhance therapeutic efficacy.
Formulations
Formulation searches look for the combination of active ingredient, excipients, release profile and dosage form. Use classification heavily: A61K 9 covers dosage forms (tablets, capsules, sustained-release systems), A61K 47 covers excipients, and A61K 31 identifies the active ingredient by its structure. Package inserts, regulatory review documents and standard excipient references are often the closest prior art. Watch section 3(e): a mere admixture that only aggregates the properties of its components is not an invention, so a formulation claim usually needs evidence of a synergistic or technical effect.
Processes
For synthetic routes, search reactions and key intermediates, not only final compounds. Process patents matter for generics: section 48 extends a process patent to products obtained directly by the process. Section 3(d) also excludes the mere use of a known process unless it results in a new product or employs at least one new reactant.
New uses
A new use of a known substance is not patentable in India under section 3(d), so there is rarely a patentability search to run. New-use patents granted elsewhere still matter for freedom to operate in those countries.
Biologics
Antibodies, peptides, enzymes and nucleic acids need sequence searching as well as keyword and classification searches (C07K, C12N). Patent sequence listings and public sequence databases both need checking, with percentage-identity thresholds agreed in advance.
Sources worth knowing
| Source | What it gives you |
|---|---|
| InPASS (Indian Patent Office) | Indian applications and patents, legal status, and documents on the file, including examination reports, pre-grant representations and Form 27 working statements |
| Espacenet, Google Patents, PATENTSCOPE, Lens | Worldwide patent documents and families; PATENTSCOPE adds chemical structure searching |
| PubChem, SureChEMBL, ChEMBL | Free structure searching, with links between compounds, patents and bioactivity data |
| Commercial chemistry databases | The most complete structure, Markush and reaction searching, at a cost |
| US FDA Orange Book and similar patent registers | Patents listed against approved drugs in those markets |
| Medicines Patent Pool's MedsPaL | Patent and licensing status of selected medicines in many low- and middle-income countries |
| PubMed, clinical trial registries, regulatory review documents and labels | Clinical, dosing and formulation disclosures outside patents |
For Indian freedom to operate, InPASS is essential. Form 3 statements on the Indian file list corresponding foreign applications, which helps you map families, and pre-grant representations show you what prior art others have already raised.
A search workflow that holds up
- Break the subject into elements: compound, form, formulation, process, use.
- Collect identifiers: INN, CAS RN, IUPAC names, SMILES or InChI, code names, brand names, and the originator company.
- Map the classification: A61K, A61P and the C07 or C12 groups, using IPCPUB and the CPC.
- Run structure searches: exact, substructure, similarity, Markush.
- Run keyword searches with synonyms and identifiers, combined with classification.
- Follow citations backwards and forwards from the closest documents, and expand to patent families.
- Search non-patent literature and regulatory sources.
- Apply the right date or status filter: before the priority date for patentability; in force or pending, by country, for FTO.
- Analyse claim by claim: novelty, inventive step, and the section 3(d) or 3(e) position.
- Write the search log so someone else could repeat the search. Our prior art search guide has a template.
A worked example: an extended-release tablet of a known drug
The example is hypothetical. A Hyderabad generic manufacturer wants to launch an extended-release tablet of a well-known antidiabetic drug in India, and to patent its own formulation if it can.
The FTO side. The search confirms the basic compound patent has expired in India. It finds three later Indian filings by the originator: a crystalline salt (granted), an extended-release formulation using a particular polymer matrix (granted), and a combination with a second drug (pending, with a pre-grant representation on file). The manufacturer's formulation uses the free base, not the salt, and a different polymer system. Claim charts against the granted formulation patent show its tablet falls outside the claims. The pending combination application is not relevant to a single-drug product but goes on the watch list.
The patentability side. The search finds extended-release tablets of the same drug using similar polymers in a journal article and two foreign patents. The manufacturer's formulation reaches steady blood levels with one daily dose using a lower polymer load. Its team will need comparative data showing a real technical effect, and should expect section 3(e) and inventive step objections. A claim focused on the specific polymer ratio and release profile, backed by dissolution and pharmacokinetic data, has a fair chance. A broad claim to "an extended-release tablet of the drug" does not.
Common mistakes
- Searching by name only, and missing the compound inside a Markush formula.
- Treating a patentability search as an FTO, or the other way round.
- Ignoring regulatory documents and labels, which often disclose formulations in detail.
- Searching patents for a new salt or polymorph without finding the known substance's efficacy data, so the section 3(d) question is left open.
- Forgetting pending Indian applications in an FTO, which may be granted before launch.
- Not checking legal status, so lapsed patents are counted as live or live ones as lapsed.
- Keeping no search log, so nobody can tell later what was and was not covered.
Checklist
- The question (patentability, FTO, validity or landscape) and the markets are written down.
- All identifiers have been collected and searched.
- Structure, substructure, similarity and Markush searches have been run where relevant.
- Classification searches cover A61K, A61P and the relevant C07 or C12 groups.
- Non-patent and regulatory sources have been searched.
- Indian filings, legal status and file documents have been checked on InPASS.
- The section 3(d) or 3(e) position is analysed with efficacy evidence in mind.
- The search log records databases, strings, dates and results.
How MYCrave can help
MYCrave Consultancy & Services runs pharmaceutical and chemical searches within its search and freedom-to-operate practice, with 8,000+ prior art searches and a Registered Patent Agent (No. 5509) on record:
- Patentability searches for compounds, forms, formulations and processes, with a section 3(d) and 3(e) assessment.
- Freedom-to-operate analysis for Indian and export launches, with claim charts and status checks.
- Validity searches for pre-grant representations and post-grant oppositions.
- Drafting and prosecution of pharmaceutical applications through our patent registration practice.
Search the chemistry, not just the words
A pharmaceutical search is only as good as the identifiers, structures and sources it covers. Decide the question first, search the structure as well as the name, read the regulatory documents, and in India always find the known substance and what it already does. That is where most pharma patents in this country are won or lost.
Need a pharma patent search?
Tell us the molecule, form or formulation, the markets you care about and whether the question is patentability, freedom to operate or validity. We will scope the search and the sources before any fee is spent. Call +91 76006 90996 or write to info@mycrave.co.in.
Scope your searchFrequently asked questions
What is a Markush search?
Can I patent a new salt or polymorph of a known drug in India?
Are free databases enough for a pharmaceutical search?
Is a new use of a known drug patentable in India?
Why do regulatory documents matter in a patent search?
How do I find pending Indian pharma applications?
Talk to a MYCrave IP expert. Free initial consultation, complete confidentiality.
Book a ConsultationAbout this guide
- The Patents Act, 1970, sections 2(1)(j), 2(1)(ja), 3(d), 3(e), 8, 25 and 107A
- Novartis AG v. Union of India (Supreme Court of India, 2013)
- WIPO, International Patent Classification (IPCPUB), classes A61K, A61P, C07 and C12
- Indian Patent Office public search, InPASS
Law checked against the Patents Act, 1970 and the Patents Rules, 2003 as amended in March 2024. Database coverage and features change; the sources named here are examples, not endorsements. Confirm the current position with the Office of the Controller General of Patents, Designs and Trade Marks.
Spotted an error? Tell us at info@mycrave.co.in and we will correct it. How we research, review and update this library is set out in our editorial policy. This guide is general information about Indian IP law and procedure, not advice on your specific matter.